Basil Systems, a leading AI-based product lifecycle intelligence platform for the life sciences industry, announced it has raised a total of $11.5 million in funding led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital.
Basil has also built the largest indexed dataset in life sciences BasilLink, with 600+ million records continuously updated, structured, and growing. And this includes regulatory submissions, global drug labels, clinical trials, adverse event reports, guidances, regulations, recalls, citations, inspections, and more.
The company’s proprietary platform answers complex questions in seconds, such as identifying which materials are most often linked to knee implant failures or comparing label changes across oncology therapies in specific patient populations. And these insights are accessible through a full-text natural language interface, with API connectivity and enterprise-grade infrastructure designed to support millions of concurrent users.
What the funding will be used for: The company will use the funding to expand its enterprise BasilIntel SaaS platform, deepen product capabilities, and accelerate the deployment of data-driven insights across the pharma and medical device industry.
This new funding round will also enable Basil to expand its data coverage, onboard additional enterprise clients, and expand the rollout of AI and machine learning to automate high-stakes, high-complexity workflows. And the company plans to broaden support to adjacent players across the life sciences ecosystem, including drug and device manufacturers, suppliers, clinical research organizations, and regulatory agencies.
Value Proposition: Life sciences companies face complex and mission-critical operations that are still burdened by manual workflows, siloed data, and outdated tools. From regulatory submissions and clinical planning to post-market surveillance and competitive analysis, critical decisions are often made without clear and timely insight. Basil Systems improves this by delivering real-time and AI-based intelligence that helps teams move faster, collaborate, reduce risk, and make smarter decisions across product development, regulatory strategy, and market execution.
Life sciences companies often struggle with siloed data spread across departments and formats, which slows down critical regulatory and product decisions. Even though many solutions promise to fix this, they’re often too complex or unreliable. Basil Systems provides a streamlined, proven approach by using proprietary machine learning algorithms to automatically ingest and unify scattered data into a single, fully indexed source of truth. And the result is faster access to insights, leaner operations, and a scalable foundation for AI-driven decision-making across the enterprise.
The BasilIntel platform is already used by 4 of the 5 largest global medical device companies and is in active trials with three of the top global pharmaceutical firms.
Along with core regulatory and clinical insights, Basil’s platform is used for strategic product development, supply chain optimization, risk mitigation, and real-world evidence (RWE) analysis. And it supports use cases across regulatory, clinical, quality, medical affairs, and commercial divisions to provide a unified system of record and intelligence.
KEY QUOTES:
“Basil Systems is transforming how life sciences companies access and act on regulatory intelligence. What once took teams weeks or months of manual effort using disconnected systems, Basil now delivers in real time by providing actionable insights that drive better product decisions, mitigate risk, and accelerate approvals. This isn’t just a workflow improvement, it’s a fundamental shift in how healthcare innovation gets to market.”
Bert Amato, Venture Partner, Golden Ventures and Board Director
“Basil Systems has built the most comprehensive, structured dataset in life sciences, with over 600 million records spanning regulatory filings, clinical trials, post-market events, drug labels, and more. Our AI-powered platform transforms that data into real-time answers for the strategic questions that drive product success. We’re not just accelerating workflows and decision making, but creating a new standard for how life sciences companies make critical decisions across innovation, regulatory, safety and commercialization.”
Anthony Cirurgiao, CEO and Founder, Basil Systems
“Basil has built a centralized intelligence engine for how medical products are developed, approved, and perform in-market. With unmatched depth in regulatory and real-world life sciences data, Basil gives companies the visibility and analytics they need to make faster, smarter decisions. It’s becoming the default infrastructure layer for data-driven strategy in life sciences.”
Mohamed Shariff, Director Regulatory Affairs, J&J
